Advertisement

Latest Recommendations of the European Germ Cell Cancer Group on Diagnosis and Treatment of Germ Cell Cancer

  • Susanne KregeEmail author

Abstract

In 2004, the first European Consensus Paper concerning diagnosis and treatment of germ cell cancer was published (Schmoll et al. Ann Oncol 15:1377–1399, 2004). The consensus group consisted of more than 60 experts from all across Europe. The experts involved were oncologists, urologic surgeons, radiooncologists, pathologists and basic scientists. Since then, regular updates were performed by the group (Krege et al. Eur Urol 53:478–496, 2008; Krege et al. Eur Urol 53:497–513, 2008), the latest published in 2012 (Beyer et al. Ann Oncol 24:878–888, 2013). In this chapter, the recent recommendations of the European group are summarized. The following chapters will present some topics in detail, which are still discussed controversial, or for which the best management is not yet found.

Keywords

Late Toxicity Germ Cell Cancer Retroperitoneal Lymph Node Metastasis Father Child Seminoma Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Schmoll H-J, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004;15:1377–99.CrossRefPubMedGoogle Scholar
  2. 2.
    Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I. Eur Urol. 2008;53:478–96.CrossRefPubMedGoogle Scholar
  3. 3.
    Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008;53:497–513.CrossRefPubMedGoogle Scholar
  4. 4.
    Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24:878–88.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Steiner H, Höltl L, Maneschg C, et al. Frozen section analysis-guided organ-sparing approach in testicular tumors: technique, feasibility, and long-term results. Urology. 2003;62:508–13.CrossRefPubMedGoogle Scholar
  6. 6.
    Heidenreich A, Weissbach L, Höltl W, et al. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol. 2001;166:2161–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Dieckmann K-P, Kulejewski M, Pichlmeier U, Loy V. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol. 2007;51:175–85.CrossRefPubMedGoogle Scholar
  8. 8.
    Dieckmann K-P, Kulejewski M, Heinemann V, et al. Testicular biopsy for early cancer detection – objectives, technique and controversies. Int J Androl. 2011;34:e7–13.CrossRefPubMedGoogle Scholar
  9. 9.
    Christensen TB, Daugaard G, Geertsen PF, et al. Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol. 1998;9:657–60.CrossRefPubMedGoogle Scholar
  10. 10.
    Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics. Tumours of the urinary system and male genital organs, WHO classification of tumours. Lyon: IARC Press; 2004.Google Scholar
  11. 11.
    Wittekind CH, Meyer H-J, editors. UICC: TNM classification of malignant tumours. 7th ed. New York: Wiley-Liss; 2010.Google Scholar
  12. 12.
    International Germ Cell Cancer Collaborative Group (IGCCCG). The International Germ Cell Consensus Classification: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol. 1997;15:594–603.Google Scholar
  13. 13.
    Hansen J, Jurik AG. Diagnostic value of multislice computed tomography and magnetic resonance imaging in the diagnosis of retroperitoneal spread of testicular cancer: a literature review. Acta Radiol. 2009;50:1064–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Huddart RA, O’Doherty MJ, Padhani A, et al. 18 fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22 – the NCRI Testis Tumour Clinical Study Group. J Clin Oncol. 2007;25:3090–5.CrossRefPubMedGoogle Scholar
  15. 15.
    De Wit M, Brenner W, Hartmann M, et al. (18F)-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol. 2008;19:1619–23.CrossRefPubMedGoogle Scholar
  16. 16.
    Gilligan T, Seidenfeld J, Basch EM. American Society of Clinical Oncology Clinical practice Guidelines on the uses of tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010;28:3388–404.CrossRefPubMedGoogle Scholar
  17. 17.
    Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002;20:4448–52.CrossRefPubMedGoogle Scholar
  18. 18.
    Lewinshtein D, Gulati R, Nelson PS, Porter CR. Incidence of second malignancies after external beam radiotherapy for clinical stage I Testicular seminoma. BJU Int. 2012;109:706–12.CrossRefPubMedGoogle Scholar
  19. 19.
    Horwich A, Fossa SD, Huddart R, et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer. 2014;110:256–63.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Oliver TD, Mead GM, Gordon JS, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 Study. J Clin Oncol. 2011;29:957–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Chung PW, Daugaard G, Tydlesley S, et al. Prognostic factors for relapse in stage I seminoma managed with surveillance: a validation study. J Clin Oncol. 2010;28:15s (abstract 4535).Google Scholar
  22. 22.
    Aparicio J, Maroto P, del Muro XG, et al. Risk adapted treatment in clinical stage I seminoma: the third Spanish germ cell cancer group study. J Clin Oncol. 2011;29:4677–81.CrossRefPubMedGoogle Scholar
  23. 23.
    Tandstad T, Stahl O, Hakansson U, et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded Results from the SWENOTECA group. Ann Oncol. 2014;25:2167–72.Google Scholar
  24. 24.
    Nicolai N, Miceli R, Necchi A, et al. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Eur Urol. 2010;58:912–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Garcia-del-Muro X, Maroto P, Guma J, et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish germ cell cancer group study. J Clin Oncol. 2008;26:5416–21.CrossRefPubMedGoogle Scholar
  26. 26.
    Culine S, Kerbat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good risk metastatic nonseminomatous germ-cell tumors: a randomised trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18:917–24.CrossRefPubMedGoogle Scholar
  27. 27.
    Grimison PS, Martin R, Stockler MR, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomised trial. J Natl Cancer Inst. 2010;102:1253–62.CrossRefPubMedGoogle Scholar
  28. 28.
    de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP versus four cycles of VIP in patients with intermediate prognosis metastatic testicular non-seminoma: a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer. 1998;78:828–32.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol. 1998;16:1287–93.PubMedGoogle Scholar
  30. 30.
    Daugaard G, Skoneczna I, Aass N, et al. A randomized phase III study comparing standard dose BEP with sequential high- dose cisplatin, etoposide, and ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol. 2011;22:1054–61.CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Motzer RJ, Nichols CJ, Margolin LA, et al. Phase III randomised trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastastic germ cell tumors. J Clin Oncol. 2007;25:247–56.CrossRefPubMedGoogle Scholar
  32. 32.
    De Santis M, Becherer A, Bokemeyer C, et al. 2–18 fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004;22:1034–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Bachner M, Loriot Y, Gross-Goupil M, et al. 2–18 fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol. 2012;23:59–64.CrossRefPubMedGoogle Scholar
  34. 34.
    Beck SD, Foster RS, Bihrle R, et al. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer. 2007;110:1235–40.CrossRefPubMedGoogle Scholar
  35. 35.
    Heidenreich A, Pfister D, Witthuhn R, et al. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol. 2009;55:217–26.CrossRefPubMedGoogle Scholar
  36. 36.
    Ravi P, Gray KP, Donnell EKO, Sweeney CJ. A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. Ann Oncol. 2014;25:331–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Besse B, Grunenwald D, Flechon A, et al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg. 2009;137:448–52.CrossRefPubMedGoogle Scholar
  38. 38.
    Schirren J, Trainer S, Eberlein M, et al. The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. J Thorac Cardiovasc Surg. 2012;60:405–12.CrossRefGoogle Scholar
  39. 39.
    Fizazi K, Oldenburg J, Dunant A, et al. Assessing prognosis and optimising treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSCGT): results of the sCR2 international study. Ann Oncol. 2008;19:259–64.CrossRefPubMedGoogle Scholar
  40. 40.
    Murphy AM, McKiernan JM. Reoperative retroperitoneal lymph-node dissection for testicular germ cell tumor. World J Urol. 2009;27:501–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Spiess PE, Kassouf W, Brown GA, et al. Surgical management of growing teratoma syndrome: the M.D. Anderson Cancer Center experience. J Urol. 2007;177:1330–4.CrossRefPubMedGoogle Scholar
  42. 42.
    Lee DJ, Djaladat H, Tadros NN, et al. Growing teratoma syndrome: clinical and radiographic characteristics. Int J Urol. 2014;21:905–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med. 2009;361:849–57.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Rustin GJ, Mead GM, Sally P, et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE 08 – The International Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol. 2007;10:1310–5.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Klinik für UrologieKliniken Essen-MitteEssenGermany

Personalised recommendations